Trials / Conditions / Moderate to Severe Psoriasis

Moderate to Severe Psoriasis

11 registered clinical trials studyying Moderate to Severe Psoriasis — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada NCT07370766	Chronicle Academy	—
Not Yet Recruiting	The Relationship Between Moderate-to-severe Psoriasis and Sleep Disturbance NCT06165887	Shanghai Yueyang Integrated Medicine Hospital	—
Completed	Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing NCT05344248	Shanghai Junshi Bioscience Co., Ltd.	Phase 1 / Phase 2
Completed	A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chr NCT03051217	UCB Biopharma S.P.R.L.	Phase 2 / Phase 3
Completed	Biologics Anchoring Study NCT03026153	Wake Forest University Health Sciences	N/A
Unknown	Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal NCT01237262	University of Padova	Phase 4
Terminated	Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After NCT01156532	AbbVie (prior sponsor, Abbott)	—
Completed	Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe NCT00936065	Pfizer	Phase 4
Completed	Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis NCT00678470	University of California, San Francisco	N/A
Completed	Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis NCT00442650	Merck KGaA, Darmstadt, Germany	Phase 3
Completed	CLEAR Study: Clinical Experience Acquired With Raptiva Study NCT00256139	Merck KGaA, Darmstadt, Germany	Phase 3